# Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis

> **NCT06329492** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 20 (actual)

## Conditions studied

- Osteoarthritis
- OA
- Knee Osteoarthritis

## Interventions

- **BIOLOGICAL:** Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)

## Key facts

- **NCT ID:** NCT06329492
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-09
- **Primary completion:** 2026-01-28
- **Final completion:** 2026-02-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329492, "Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06329492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*